RxDoctor Payments Data

Sunil Goli, MD

Neurology · Alabaster, ALNPI 1124045083

Payments from drug & device makers

$5,758in general payments, 2019–2025

Across 242 payments — averaging $23.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$472
  • Argenx US, Inc.$459
  • Pfizer$402
  • Teva Pharmaceuticals USA, Inc.$389
  • Lilly USA, LLC$369
  • Harmony Biosciences LLC$336
  • plus $3K from 30 others

What the payments were for

  • Speaking & faculty fees$240%
  • Food & beverage$5,58397%
  • Education$1513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,758 in reported general payments places this provider in the 55th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$94,636
Medicare patients
273
Services billed
916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate24$36,874
Aimovig AutoinjectorErenumab-Aooe26$18,673
Levetiracetam149$5,713
Lacosamide39$3,559
Carbidopa-LevodopaCarbidopa/Levodopa111$3,503
Carbamazepine ErCarbamazepine11$3,334
Memantine Hcl98$3,129
Modafinil54$2,962
Gabapentin217$2,749
Pramipexole DihydrochloridePramipexole Di-Hcl175$2,719
Carbidopa-Levodopa ErCarbidopa/Levodopa28$2,459
Oxcarbazepine14$1,869
Doxepin Hcl28$1,833
Primidone61$1,614
RivastigmineRivastigmine Tartrate20$1,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$402$36,87424 claims
Upsher-smith Laboratories LLCTopiramate$48$41037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 255 neurology providers in Alabama.

Other neurology in Alabaster

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →